Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue
- 1 January 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 4 (1), 221-233
- https://doi.org/10.2215/cjn.02550508
Abstract
Cardiovascular disease is highly prevalent in chronic kidney disease (CKD) and is often associated with increased vascular stiffness and calcification. Recent studies have suggested a complex interaction between vascular calcification and abnormalities of bone and mineral metabolism, with an inverse relationship between arterial calcification and bone mineral density (BMD). Although osteoporosis is recognized and treated in CKD 1 to 3, the interpretation of BMD levels in the osteoporotic range is controversial in CKD 4, 5, and 5D when renal osteodystrophy is generally present. In addition, there is a paucity of data for patients with CKD mineral and bone disorder (MBD), because studies using bisphosphonates in postmenopausal and glucocorticoid-induced osteoporosis have generally excluded patients with significant CKD. For these patients, treatment of low BMD using standard therapies for osteoporosis is not without potential for harm due to the possibility of worsening low bone turnover, osteomalacia, mixed uraemic osteodystrophy, and of exacerbated hyperparathyroidism; and bisphosphonates should only be used selectively and with caution. Some experimental and clinical studies have also suggested that bisphosphonates may reduce progression of extra-osseous calcification and inhibit the development of atherosclerosis. The authors review the potential benefits and risks associated with bisphosphonate use for bone protection in CKD, and assess their effect on vascular calcification and atherosclerosis.Keywords
This publication has 101 references indexed in Scilit:
- Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosisBone, 2007
- Pulse Wave Velocity Is Inversely Related to Vertebral Bone Density in Hemodialysis PatientsHypertension, 2007
- Bisphosphonates in the renal patientNephrology Dialysis Transplantation, 2007
- Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD)Nephrology Dialysis Transplantation, 2006
- Inhibition of the Progression of Aortic Calcification by Etidronate Treatment in Hemodialysis Patients: Long‐Term EffectsTherapeutic Apheresis and Dialysis, 2006
- Osteonecrosis of the Jaw and BisphosphonatesThe New England Journal of Medicine, 2005
- Alternative bisphosphonate targets and mechanisms of actionBiochemical and Biophysical Research Communications, 2005
- Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failureNephrology Dialysis Transplantation, 2004
- Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal DiseaseHypertension, 2001
- Idiopathic infantile arterial calcification in siblings: Radiologic diagnosis and successful treatmentThe Journal of Pediatrics, 1978